Anti-human α9 Integrin Antibody for Disease Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic drugs for cancers, inflammatory diseases, infectious diseases, autoimmune diseases, and bone diseases have limitations in efficacy, and there is a need for improved prophylactic and therapeutic agents that specifically target α9 integrin to enhance treatment outcomes.
Innovation Solution
Development of a novel monoclonal antibody specifically targeting human α9 integrin, produced by hybridoma cells, which inhibits α9 integrin activity, and its use in therapeutic and diagnostic agents to treat various diseases by interfering with the binding between α9 integrin and its ligands.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current therapeutic drugs are used for cancers, inflammatory diseases, infectious diseases, autoimmune diseases, and bone diseases, then treatment is provided, but efficacy is limited
Solution Approach 1:
The patent changes the therapeutic parameter by targeting a specific molecular marker (α9 integrin) rather than using broad-spectrum drugs. This specific targeting approach improves therapeutic efficacy for multiple disease types by interfering with the binding between α9 integrin and its ligands, thereby providing both improved reliability and adaptability across different disease conditions.
2Adaptability or versatility
If general therapeutic approaches are used, then broad disease coverage is achieved, but specific therapeutic effect is limited
Solution Approach 1:
The patent applies local quality by creating a therapeutic agent with specific molecular recognition capability. The anti-α9 integrin antibody selectively binds to α9 integrin expressed in specific tissues and cells involved in various diseases, providing localized and specific therapeutic action while maintaining broad adaptability across different disease types that share the α9 integrin pathway.
3Reliability
If α9 integrin targeting is implemented, then therapeutic effect is improved, but mechanism complexity increases
Solution Approach 1:
The patent uses an anti-α9 integrin antibody as an intermediary molecule to block the interaction between α9 integrin and its ligands. This intermediary approach simplifies the therapeutic mechanism compared to directly modulating integrin function, as the antibody serves as a readily available tool that can be administered systemically to achieve the desired therapeutic effect across multiple disease types.
Data Source
AI summary
The present invention relates to an anti-human α9 integrin antibody. More particularly, the present invention relates to: a monoclonal antibody, a chimeric antibody, a humanized antibody and a human antibody that specifically recognize human α9 integrin; a hybridoma cell that produces the monoclonal antibody; a method for producing the monoclonal antibody; a method for producing the hybridoma cell; a therapeutic agent comprising the anti-human α9 integrin antibody; a diagnostic agent comprising the human α9 integrin antibody; and a method for screening for a compound that inhibits the activity of human α9 integrin.